CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston (1). Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets r...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02235/full |
| _version_ | 1818827843896868864 |
|---|---|
| author | Edward A. Clark Edward A. Clark Natalia V. Giltiay |
| author_facet | Edward A. Clark Edward A. Clark Natalia V. Giltiay |
| author_sort | Edward A. Clark |
| collection | DOAJ |
| description | CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston (1). Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets regulated by CD22 or Siglec G (2–4). This review is an attempt to highlight recent and possibly forgotten findings. We also describe the role of CD22 in autoimmunity and the great potential for CD22-based immunotherapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE). |
| first_indexed | 2024-12-19T00:50:00Z |
| format | Article |
| id | doaj.art-1802002d53fd481db46bddb78b39587c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T00:50:00Z |
| publishDate | 2018-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1802002d53fd481db46bddb78b39587c2022-12-21T20:44:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-09-01910.3389/fimmu.2018.02235413314CD22: A Regulator of Innate and Adaptive B Cell Responses and AutoimmunityEdward A. Clark0Edward A. Clark1Natalia V. Giltiay2Department of Immunology, University of Washington, Seattle, WA, United StatesDivision of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, United StatesDivision of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, United StatesCD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston (1). Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets regulated by CD22 or Siglec G (2–4). This review is an attempt to highlight recent and possibly forgotten findings. We also describe the role of CD22 in autoimmunity and the great potential for CD22-based immunotherapeutics for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE).https://www.frontiersin.org/article/10.3389/fimmu.2018.02235/fullCD22B cellsautoimmunityantigensTLR7T cell dependent |
| spellingShingle | Edward A. Clark Edward A. Clark Natalia V. Giltiay CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity Frontiers in Immunology CD22 B cells autoimmunity antigens TLR7 T cell dependent |
| title | CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity |
| title_full | CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity |
| title_fullStr | CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity |
| title_full_unstemmed | CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity |
| title_short | CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity |
| title_sort | cd22 a regulator of innate and adaptive b cell responses and autoimmunity |
| topic | CD22 B cells autoimmunity antigens TLR7 T cell dependent |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2018.02235/full |
| work_keys_str_mv | AT edwardaclark cd22aregulatorofinnateandadaptivebcellresponsesandautoimmunity AT edwardaclark cd22aregulatorofinnateandadaptivebcellresponsesandautoimmunity AT nataliavgiltiay cd22aregulatorofinnateandadaptivebcellresponsesandautoimmunity |